CPI-613 in Combination With High Dose ARA-C and Mitoxantrone

Video

Bayard L. Powell, MD, discusses a phase I study that looked at CPI-613 in combination with high dose ARA-C and mitoxantrone for the treatment of patents with relapsed/refractory acute myeloid leukemia (AML).

Clinical Pearls

Bayard L. Powell, MD, Section Chief, Hematology & Oncology, Director, Leukemia Service, Wake Forest University, discusses aphase I studythat looked atCPI-613in combination with high dose ARA-C and mitoxantrone for the treatment of patents with relapsed/refractory acute myeloid leukemia (AML).

  • It is feasible to add CPI-613 to high dose ARA-C and mitoxantrone. No additional toxicity was observed.
  • Approximately 50% of patients responded to this combination.
  • Older patients and patients with high-risk cytogenetics typically do not respond well to high dose ARA-C and mitoxantrone. With the addition of CPI-613, the response rate was about the same in these groups compared with the entire population.
Recent Videos
Related Content
Brexu-cel Achieves Strong CNS and Systemic Responses in Adult B-ALL Patients

Brexu-cel Achieves Strong CNS and Systemic Responses in Adult B-ALL Patients

Jordyn Sava
November 22nd 2024
Article

Ibrahim N. Muhsen, MD, evaluated the efficacy of brexu-cel in adult patients with central nervous system involvement in relapsed/refractory B-cell acute lymphoblastic leukemia.

Read More

FGFR-Altered NMIBC Treatment Advances With TAR-210 Findings

FGFR-Altered NMIBC Treatment Advances With TAR-210 Findings

Jordyn Sava
November 21st 2024
Article

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.

Read More

Improving Outcomes Using Ribociclib in High-Risk Node-Negative Breast Cancer

Improving Outcomes Using Ribociclib in High-Risk Node-Negative Breast Cancer

Jordyn Sava
November 21st 2024
Article

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node involvement who were enrolled in the phase 3 NATALEE trial.

Read More

Optimizing Treatment in Myeloma With Biweekly Dosing of Talquetamab

Optimizing Treatment in Myeloma With Biweekly Dosing of Talquetamab

Jordyn Sava
November 20th 2024
Article

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma.

Read More

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Jonah Feldman
November 15th 2024
Article

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

Read More

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Morgan Bayer
November 14th 2024
Article

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

Read More